Efficacy of Sildenafil Therapy in Pulmonary Artery Hypertension: A Meta-Analysis

Objective To evaluate efficacy of Sildenafil in treatment of pulmonary hypertension, in order to guide the clinical work. Methods Study was conducted on the articles relating to the analysis of Sildenafil and pulmonary hypertension for comparisons and study from the China Journal Full-text Database and PubMed professional foreign language database collected from 2000 to November 2012. Chose the right articles, and analyzed it with RevMan 5.1 software. Results This article encompasses 9 studies. The meta-analysis Results of the experimental group and the placebo group show that: （1） To improve the pulmonary artery pressure, there is statistically significance, WMD = -14.32 mmHg, 95%CI （-20.56, -8.08） mmHg, P< 0.000 01. （2） To increase the 6 minutes walking distance, there is statistical significance, WMD=62.78 m, 95%CI （46.79, 78.78） m, P< 0.000 01. （3） To reduce the right atrial pressure has no statistical significance, WMD=-3.30 mmHg, 95%CI （-8.22, 1.63） mmHg, P=0.19. （4） To increase the cardiac index is statistically significant, WMD=0.96 L/（min·m2）, 95%CI （0.91, 1.01） L/（min·m2）, P< 0.000 01. （5） To reduce the dyspnea index has no statistical significance, WMD=-0.28, 95% CI （-2.36,1.79）, P=0.79. Conclusion Sildenafil in the treatment of pulmonary hypertension to reduce pulmonary artery pressure, enhance the 6 minutes walking distance and cardiac index produced better efficacy than in the non-Sildenafil group.